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Prediagnostic selenium concentrations measured in archived toenails were inversely associated with bladder cancer risk in women
(P for trend¼0.02), but not in men, in a nested case–control study of 338 cases and 341 matched controls. These findings may be due
to chance and more studies are needed to determine whether associations between selenium and bladder cancer risk differ by sex.
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Data from animal studies, observational studies and clinical trials
suggest that selenium is anticarcinogenic and can reduce the risk
of a number of different cancers (Combs, 2005). Five studies,
each with fewer than 36 bladder cancer cases, reported incon-
sistent findings for selenium measured in serum (Nomura et al,
1987; Helzlsouer et al, 1989), toenails (Knekt et al, 1990; Garland
et al, 1995), or given as supplements in an intervention trial (Clark
et al, 1996). In two large cohort studies with selenium measure-
ments from prediagnosic toenail samples, no association was
observed with bladder cancer risk among male smokers (Michaud
et al, 2002), but a strong inverse association was reported in a
study conducted in the Netherlands (Zeegers et al, 2002).
Of the two largest studies to date, only 59 women were available
for analysis in one study (Zeegers et al, 2002) and the other study
consisted only of men (Michaud et al, 2002). We examined the sex-
specific association between prediagnostic toenail selenium and
bladder cancer risk using data from two large cohort studies.
MATERIALS AND METHODS
The Health Professionals Follow-Up Study (HPFS) and the Nurses’
Health Study (NHS) cohorts provided data for our analyses of
toenail selenium concentrations and bladder cancer risk. Details
on these two cohorts have been previously published (Michaud
et al, 2001). Toenail clippings were obtained from 33737 HPFS
participants in 1987 and from 68213 NHS participants in 1983.
At baseline, participants of these cohorts provided information
on disease history, history of cigarette smoking, medication use,
weight and height. In addition, smoking status is updated
biennially. The National Death Index was used to determine
vital status for nonrespondents, and the remaining nonrespon-
dents were assumed to be alive and at risk for bladder cancer
incidence.
Participants report new medical conditions on a biennial basis.
Self-reported bladder cancers are confirmed by review of medical
records (87%) or with an additional letter or phone call. Similar
procedures are followed when the National Death Index lists a
previously unreported bladder cancer for a deceased participant.
Participants with bladder cancer were eligible for this analysis
if the cancer diagnosis occurred after the toenail samples were
obtained and they had no prior history of cancer (other than
nonmelanoma skin cancer). From the time of the toenail collection
through 2000, 338 incident cases with toenail samples were
available for the selenium analyses (222 men; 116 women).
Controls were matched (1:1) on gender, age (within 1 year),
smoking status (current, past, never, unknown) and month of
toenail collection. In addition, controls had to be cancer free (other
than nonmelanoma skin cancer) at the time of the bladder cancer
diagnosis in the matched case.
Selenium concentrations were measured in two batches by Dr
Morris at the University of Missouri Research Reactor, Columbia,
MO, USA, using neutron activation analysis (NAA) (Baskett et al,
1995). For quality control, selenium was measured in NIST SRM
1577, giving 1.08870.065mgg
 1 (n¼24, in the first batch) and
1.10870.031mgg
 1 (n¼8, in second batch) vs a certified value of
1.170.1. The CV% for these quality controls was 6.0 and 2.8 for
the first and second batches, respectively. In addition, we obtained
a CV% of 5.7 for 24 internal controls (split toenail samples), which
were blinded to the laboratory.
Odds ratios (OR) and 95% confidence intervals (CI) were
estimated using conditional logistic regression models. Quartiles of
selenium concentrations were created according to the distribution
of the controls for each sex, separately. A continuous variable for
pack-years of smoking was additionally included in all models. As
a secondary analysis, we performed analyses with a 4-year lag to
exclude preclinical cases at baseline. All P-values are based on two-
sided statistical tests. We performed tests for trend by assigning
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RESULTS
Mean selenium toenail concentrations were higher in men than
women (0.896 vs 0.787mgg
 1, among controls, respectively), but
similar among cases and controls for each sex (Table 1). Even
though cases and controls were matched on smoking status (never,
past, current), pack-years of smoking (among past and current
smokers) were higher among cases than controls. Among women,
menopausal status and age at menopause were similar in cases and
controls.
In a conditional regression model, higher toenail selenium con-
centrations were associated with significantly lower risk of bladder
cancer in women (P for trend¼0.02), but not in men (Table 2).
Median selenium concentrations varied by smoking status (HPFS
(mgg
 1): never 0.825, past 0.814, current 0.739; NHS (mgg
 1): never
0.777, past 0.785, current 0.716). Among women, the strongest
association between selenium and bladder cancer was observed
among past smokers (RR¼0.17, 95% CI¼0.04–0.74 for the
highest tertile of selenium, compared to the lowest); among men,
smoking status did not significantly modify the associations (data
not shown).
Removing cases diagnosed with bladder cancer within the first 4
years of follow-up strengthened the inverse association in women
(RR¼0.27, 95% CI¼0.10–0.74, highest vs lowest quartile), but
resulted in a positive association in men (RR¼1.53, 95%
CI¼0.71–3.28, highest vs lowest quartile).
DISCUSSION
In this nested case–control, a strong inverse association was
observed between toenail selenium concentrations and bladder
cancer risk in women, but no association was observed in men.
The association, in women, was strongest among past smokers.
In the largest study to date on toenail selenium concentrations
and bladder cancer, only 59 cases (out of 431 cases) were women
and associations were not presented separately by sex (Zeegers
et al, 2002). In that study, conducted in the Netherlands between
1986 and 1992, mean toenail selenium concentrations were
substantially lower than ours, in both men and women (0.536 for
men, 0.568 for women). A relative risk of 0.67 (95% CI¼0.46–0.97)
was reported for the highest vs lowest quintile of selenium toenail
level; the strongest association was among those who recently
quit smoking (p10 years) and no associations were noted for
never and current smokers. Our findings for women were similar
to these as the inverse associations were also strongest among past
smokers.
Data from animal studies, epidemiologic data and human
prevention trials suggest that selenium is an important chemo-
preventive agent (Combs, 2005). Although the exact mechanism by
which selenium prevents cancer is unknown, multiple mechanisms
are likely to be involved. At least part of the antimutagenic effect of
Table 2 Relative risks (95% confidence intervals) of bladder cancer associated with prediagnostic toenail selenium concentrations in a nested case–
control study of the NHS and HPFS cohorts
12 3 4 P-value, trend test
Men
Median selenium level (mgg
 1)
a 0.660 0.765 0.863 0.990
Case/control 52/55 54/57 53/55 62/56
RR
b 1.0 1.04 1.05 1.19 0.50
RR
c 1.0 1.09 1.08 1.17 0.61
95% CI Ref. 0.59–2.01 0.59–2.00 0.66–2.07
Women
Median selenium level (mgg
 1)
a 0.626 0.716 0.800 0.933
Case/control 37/28 35/31 23/29 21/29
RR
b 1.0 0.80 0.49 0.42 0.04
RR
c 1.0 0.73 0.49 0.36 0.02
95% CI Ref. 0.35–1.55 0.21–1.16 0.14–0.91
NHS¼Nurses’ Health Study; HPFS¼Health Professionals Follow-Up Study; RR¼relative risk; CI¼confidence interval.
aQuartile cutpoints for men: o0.723; 0.723–0.805;
0.806–0.911; 40.911; and women: o0.687; 0.687–0.763; 0.764–0.839; 40.839.
bConditional regression analysis (matched factors: age, month of toenail collection, smoking
status).
cAdditionally controlling for pack-years smoked (continuous) and current heavy cigarette smoking at baseline (25+ per day).
Table 1 Prediagnostic toenail selenium level and baseline characteristics
of nested bladder cancer cases and matched controls from the NHS and
HPFS cohort studies
Mean (s.d.) or %
Cases Controls
Men
No. of subjects 222 224
Toenail selenium level (mgg
 1)
a 0.897 (0.53) 0.896 (0.58)
Median 0.814 0.805
Age (years)
b 62.3 (8.6) 62.3 (8.6)
Smoking (%)
b
Never 26.1 25.9
Past 53.6 54.0
Current 16.7 16.5
Missing 3.6 3.6
Pack-years
c 34.1 (22.9) 29.6 (23.5)
Women
No. of subjects 116 117
Toenail selenium level (mgg
 1) 0.802 (0.50) 0.787 (0.19)
Median 0.733 0.763
Age (years)
b 53.7 (6.0) 53.7 (6.1)
Smoking (%)
b
Never 26.5 26.5
Past 23.9 24.8
Current 48.7 47.9
Missing 0.9 0.9
Pack-years
c 31.7 (22.9) 24.6 (17.8)
Premenopausal 21 22
Postmenopausal 74 71
Dubious/missing 5 7
Age at menopause
d 48.9 (4.2) 49.4 (3.5)
NHS¼Nurses’ Health Study; HPFS¼Health Professionals Follow-Up Study;
s.d.¼standard deviation.
aBased on 221 cases and 223 controls.
bMatched factors
(age at time of toenail collection, smoking status in 1986 for men and 1980 for
women).
cAmong past and current smokers.
dAmong natural postmenopausal
women (55 cases and 49 controls).
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thione peroxidases and thioredoxin reductases, which protect DNA
from oxygen radicals (Combs and Gray, 1998). In Se-adequate
individuals, the anticarcinogenic effect of selenium may be
mediated by selenium metabolites which can influence carcinogen
metabolism, immune function, tumour growth, apoptosis induc-
tion (Combs and Gray, 1998) and DNA methylation (Schrauzer,
2000).
The different results observed in men and women may be due to
a chance inverse association in women. Alternatively, a possible
explanation for the lack of association in men in our study could
be that selenium offers no additional protection within the
observed range of selenium concentrations. Mean selenium
concentrations were slightly higher in men than women in our
study and substantially higher than those previously reported in
the bladder study conducted in the Netherlands (Zeegers et al,
2002). The large sex differences in incidence rates that exist for this
cancer suggest that important etiologic differences exist between
men and women; thus, it is plausible that the association between
selenium and bladder cancer varies by sex. An alternative
possibility is that the difference is due to the timing of the toenail
collection. On average, women in the NHS provided toenails when
they were 81
2 years younger than when men in the HPFS provided
toenails (Table 1), and consequently this difference may have
provided a better measure of early exposure for women.
A limitation to our study includes possible measurement
error when assessing toenail selenium concentrations, which
may have resulted in the null finding in men. However, because
toenails from the two different cohorts were analysed at the same
time for each of the two batches, and CV% were good for both
batches, it is unlikely that this could explain the different results
by sex.
Strengths of this study include the largest number of female
bladder cancer cases to date with selenium data, pre-diagnostic
measurements, use of toenails (where selenium is more time-
integrated), detailed data on potential confounders, 1:1 matching
by known confounders and high follow-up rates in the two cohorts
used to select cases and controls.
In summary, we observed a statistically significant inverse
association between prediagnostic selenium toenail concentrations
and risk of bladder cancer in women, but not in men. To date, this
is the largest study to report findings on selenium concentrations
and bladder cancer risk in women. Future studies are needed to
confirm our findings.
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